Cefiderocol: A ray of hope for treatment of multidrug resistant gram negative bacteria
- Author Dr. Amiya
- Co-Author Dr. Anjali
- DOI http://wwj
- Country : India
- Subject : Pharmacology
Keywords : Cefiderocol, complicated urinary tract infections (cUTI), Gram-negative bacteria, Multi drug resistance (MDR)
Abstract
Cefiderocol is a novel, first in its class, siderophore antibacterial with activity against carbapenem-resistant gram-negative bacteria. Its unique structure and mechanism provide increased stability against beta lactamases. Presence of multi-drug resistance makes management of gram-negative infections difficult to treat due to the limited treatment options available. Cefiderocol has been approved by US Food and Drug Administration on 14 November 2019 for the treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including kidney infections caused by susceptible Gram-negative microorganisms, who have limited or no alternative treatment options. The purpose of this article is to review data on the mechanism of action, pharmacokinetics, pharmacodynamics, efficacy, and safety of cefiderocol.
Comments
No have any comment !